Cyberonics Refocuses Sales And Marketing Effort On Epilepsy Treatment
This article was originally published in The Gray Sheet
Executive Summary
Cyberonics will emphasize the epilepsy indication of its VNS vagus nerve stimulation implant in the wake of reimbursement difficulties that have hindered marketing of its depression indication